Since XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) and Mirati Therapeutics Inc. (NASDAQ:MRTX) are part of the Biotechnology industry, they are influenced by compare. The influences particularly affect the profitability, analyst recommendations, risk, institutional ownership, dividends, earnings and valuation of both companies.
Valuation and Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|XTL Biopharmaceuticals Ltd.||2||0.00||N/A||1.16||1.69|
|Mirati Therapeutics Inc.||83||636.40||N/A||-3.83||0.00|
Table 1 showcases the gross revenue, earnings per share and valuation of XTL Biopharmaceuticals Ltd. and Mirati Therapeutics Inc.
Table 2 hightlights the net margins, return on assets and return on equity of the two companies.
|Net Margins||Return on Equity||Return on Assets|
|XTL Biopharmaceuticals Ltd.||0.00%||70.3%||68.6%|
|Mirati Therapeutics Inc.||0.00%||-52.1%||-47.4%|
Risk and Volatility
XTL Biopharmaceuticals Ltd. has a beta of 1.07 and its 7.00% more volatile than S&P 500. In other hand, Mirati Therapeutics Inc. has beta of 1.97 which is 97.00% more volatile than S&P 500.
The Current Ratio and a Quick Ratio of XTL Biopharmaceuticals Ltd. are 51.1 and 51.1. Competitively, Mirati Therapeutics Inc. has 12.2 and 12.2 for Current and Quick Ratio. XTL Biopharmaceuticals Ltd.’s better ability to pay short and long-term obligations than Mirati Therapeutics Inc.
The Recommendations and Ratings for XTL Biopharmaceuticals Ltd. and Mirati Therapeutics Inc. are featured in the next table.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|XTL Biopharmaceuticals Ltd.||0||0||0||0.00|
|Mirati Therapeutics Inc.||0||1||2||2.67|
Competitively Mirati Therapeutics Inc. has a consensus price target of $85.25, with potential downside of -0.30%.
Insider & Institutional Ownership
XTL Biopharmaceuticals Ltd. and Mirati Therapeutics Inc. has shares owned by institutional investors as follows: 11.6% and 0%. 1% are XTL Biopharmaceuticals Ltd.’s share owned by insiders. On the other hand, insiders owned about 0.2% of Mirati Therapeutics Inc.’s shares.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|XTL Biopharmaceuticals Ltd.||-0.88%||-15.78%||-17.6%||-13.17%||26.59%||13.43%|
|Mirati Therapeutics Inc.||6.08%||0.4%||76.33%||61.65%||68.74%||149.41%|
For the past year XTL Biopharmaceuticals Ltd. was less bullish than Mirati Therapeutics Inc.
On 5 of the 9 factors XTL Biopharmaceuticals Ltd. beats Mirati Therapeutics Inc.
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and SjogrenÂ’s syndrome. The company also develops recombinant human erythropoietin for the treatment of multiple myeloma patients. XTL Biopharmaceuticals Ltd. has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was founded in 1993 and is headquartered in Raanana, Israel.
Mirati Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of oncology products. The companyÂ’s clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors. Its clinical stage product candidates also comprise sitravatinib, an orally-bioavailable, potent, small molecule spectrum-selective kinase inhibitor, which is in Phase II clinical trials for the treatment of solid tumors, such as NSCLC and metastatic Renal Cell Carcinoma, as well as in Phase Ib clinical trials to treat NSCLC patients with RET, CHR4q12, CBL, and AXL genetic alterations; and mocetinostat, an orally administered spectrum-selective Class 1 histone deacetylase inhibitor, which is in Phase Ib/II clinical trials in combination with durvalumab for the treatment of patients with NSCLC. The company has a collaboration agreement with Foundation Medicine, Inc. and Guardant Health, Inc. to explore development of their platforms as companion diagnostics for glesatinib. Mirati Therapeutics, Inc. is headquartered in San Diego, California.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.